Skip NavigationSkip to Content
Return Return to Search Results

A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis

  1. Author:
    Pappa, Vasiliki
    Bouchla, Anthi
    Terpos, Evangelos [ORCID]
    Thomopoulos, Thomas P
    Rosati, Margherita
    Stellas, Dimitris [ORCID]
    Antoniadou, Anastasia
    Mentis, Andreas
    Papageorgiou, Sotirios G [ORCID]
    Politou, Marianna
    Kotanidou, Anastasia [ORCID]
    Kalomenidis, Ioannis [ORCID]
    Poulakou, Garyfalia
    Jahaj, Edison [ORCID]
    Korompoki, Eleni [ORCID]
    Grigoropoulou, Sotiria
    Hu, Xintao [ORCID]
    Bear, Jenifer
    Karaliota, Sevasti
    Burns, Robert
    Pagoni, Maria
    Trontzas, Ioannis
    Grouzi, Elisavet
    Labropoulou, Stavroula
    Stamoulis, Kostantinos
    Bamias, Aristotelis [ORCID]
    Tsiodras, Sotirios
    Felber, Barbara K
    Pavlakis, George N
    Dimopoulos, Meletios- Athanasios [ORCID]

  2. Author Address

    Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece., Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA., National Hellenic Research Foundation, Institute of Chemical Biology, 11635 Athens, Greece., Fourth Department of Internal Medicine, University General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece., National Influenza Reference Laboratory of Southern Greece, Hellenic Pasteur Institute, 11521 Athens, Greece., Hematology Laboratory-Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece., First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece., 3rd Department of Internal Medicine, Sotiria General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece., Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA., Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., Haematology-Lymphomas Department and BMT Unit, Evangelismos Hospital, 10676 Athens, Greece., Transfusion Service and Clinical Hemostasis of Saint Savvas, Oncology Hospital of Athens, 11522 Athens, Greece., Hellenic National Blood Transfusion Center, 13678 Athens, Greece.,
    1. Year: 2021
    2. Date: Apr 11
  2. Journal: Microorganisms
    1. 9
    2. 4
  4. Type of Article: Article
  5. Article Number: ARTN 806
  6. ISSN: 2076-2607
  1. Abstract:

    COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (n = 59) to a control group (n = 59). Sixty patients received CP within a median time of 7 days from symptom onset. During a median follow-up of 28.5 days, 56/60 patients fully recovered and 1 patient remained in the ICU. The death rate in the CP group was 3.4% vs. 13.6% in the control group. By multivariate analysis, CP recipients demonstrated a significantly reduced risk of death [HR: 0.04 (95% CI: 0.004-0.36), p: 0.005], significantly better overall survival by Kaplan-Meir analysis (p < 0.001), and increased probability of extubation [OR: 30.3 (95% CI: 2.64-348.9), p: 0.006]. Higher levels of antibodies in the CP were independently associated with significantly reduced risk of death. CP infusion was safe with only one grade 3 adverse event (AE), which easily resolved. CP used early may be a safe and effective treatment for patients with severe COVID-19 (trial number NCT04408209).

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/microorganisms9040806
  3. PMID: 33920489
  4. PMCID: PMC8069820
  5. View record in Web of Science®
  6. WOS: 000643324800001
  7. PII : microorganisms9040806

Library Notes

NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel